Literature DB >> 18172746

Diagnosis of Fabry disease via analysis of family history.

Dawn A Laney1, Paul M Fernhoff.   

Abstract

Fabry disease is an X-linked lysosomal storage condition caused by a deficiency of alpha-galactosidase A. In order to determine the average number of family members who are diagnosed with Fabry disease following the diagnosis of a proband, four lysosomal storage disease centers across the United States reviewed the completed pedigrees of their Fabry disease patients. In addition, data from three Fabry disease families from other centers were submitted by patients directly. The pedigree review found 74 probands (54 males and 20 females) who had 357 diagnosed family members, of which 223 were female (60.5%) and 146 were male (39.5%). Analysis found that, on average, there were five family members diagnosed with Fabry disease for every proband. Now that enzyme replacement therapy (ERT) is available for the treatment of Fabry disease, this finding emphasizes the need for all health care professionals to ensure a detailed pedigree has been constructed for each patient affected by Fabry disease and to encourage testing and evaluation of all at-risk family members.

Entities:  

Mesh:

Year:  2008        PMID: 18172746     DOI: 10.1007/s10897-007-9128-x

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  13 in total

1.  Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.

Authors:  K D MacDermot; A Holmes; A H Miners
Journal:  J Med Genet       Date:  2001-11       Impact factor: 6.318

2.  Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors.

Authors:  Robin L Bennett; Kimberly A Hart; Erin O'Rourke; John A Barranger; Jack Johnson; Kay D MacDermot; Gregory M Pastores; Robert D Steiner; Ravi Thadhani
Journal:  J Genet Couns       Date:  2002-04       Impact factor: 2.537

3.  Natural history of Fabry disease in females in the Fabry Outcome Survey.

Authors:  P B Deegan; A F Baehner; M-A Barba Romero; D A Hughes; C Kampmann; M Beck
Journal:  J Med Genet       Date:  2005-10-14       Impact factor: 6.318

4.  Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.

Authors:  C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick
Journal:  N Engl J Med       Date:  2001-07-05       Impact factor: 91.245

5.  Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.

Authors:  C Whybra; C Kampmann; I Willers; J Davies; B Winchester; J Kriegsmann; K Brühl; A Gal; S Bunge; M Beck
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

6.  The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.

Authors:  Surya Gupta; Markus Ries; Steven Kotsopoulos; Raphael Schiffmann
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

Review 7.  Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.

Authors:  Robert J Desnick; Roscoe Brady; John Barranger; Allan J Collins; Dominique P Germain; Martin Goldman; Gregory Grabowski; Seymour Packman; William R Wilcox
Journal:  Ann Intern Med       Date:  2003-02-18       Impact factor: 25.391

8.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

Review 9.  Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

Authors:  Christine M Eng; Dominique P Germain; Maryam Banikazemi; David G Warnock; Christoph Wanner; Robert J Hopkin; Jan Bultas; Philip Lee; Katherine Sims; Scott E Brodie; Gregory M Pastores; Joerg M Strotmann; William R Wilcox
Journal:  Genet Med       Date:  2006-09       Impact factor: 8.822

10.  Comparison of health-related quality of life between heterozygous women with Fabry disease, a healthy control population, and patients with other chronic disease.

Authors:  Natalie Jansen Street; Michael S Yi; Laurie A Bailey; Robert J Hopkin
Journal:  Genet Med       Date:  2006-06       Impact factor: 8.822

View more
  20 in total

1.  Newborn Screening for Lysosomal Storage Disorders: Views of Genetic Healthcare Providers.

Authors:  Emily C Lisi; Shawn E McCandless
Journal:  J Genet Couns       Date:  2015-08-29       Impact factor: 2.537

2.  Awareness of Fabry disease among rheumatologists--current status and perspectives.

Authors:  Rolando Cimaz; Severine Guillaume; Max J Hilz; Gerd Horneff; Bernhard Manger; J Carter Thorne; Anette Torvin Møller; Nico M Wulffraat; Johannes Roth
Journal:  Clin Rheumatol       Date:  2011-04       Impact factor: 2.980

3.  Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors.

Authors:  Dawn A Laney; Robin L Bennett; Virginia Clarke; Angela Fox; Robert J Hopkin; Jack Johnson; Erin O'Rourke; Katherine Sims; Gerald Walter
Journal:  J Genet Couns       Date:  2013-07-17       Impact factor: 2.537

4.  Experiences of Being Heterozygous for Fabry Disease: a Qualitative Study.

Authors:  Charlotte von der Lippe; Jan C Frich; Anna Harris; Kari Nyheim Solbrække
Journal:  J Genet Couns       Date:  2016-03-07       Impact factor: 2.537

Review 5.  The benefits and challenges of family genetic testing in rare genetic diseases-lessons from Fabry disease.

Authors:  Dominique P Germain; Sergey Moiseev; Fernando Suárez-Obando; Faisal Al Ismaili; Huda Al Khawaja; Gheona Altarescu; Fellype C Barreto; Farid Haddoum; Fatemeh Hadipour; Irina Maksimova; Mirelle Kramis; Sheela Nampoothiri; Khanh Ngoc Nguyen; Dau-Ming Niu; Juan Politei; Long-Sun Ro; Dung Vu Chi; Nan Chen; Sergey Kutsev
Journal:  Mol Genet Genomic Med       Date:  2021-04-09       Impact factor: 2.183

Review 6.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

Review 7.  Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel.

Authors:  Alessandro P Burlina; Katherine B Sims; Juan M Politei; Gary J Bennett; Ralf Baron; Claudia Sommer; Anette Torvin Møller; Max J Hilz
Journal:  BMC Neurol       Date:  2011-05-27       Impact factor: 2.474

8.  Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021.

Authors:  Cassiano Augusto Braga Silva; Luis Gustavo Modelli de Andrade; Maria Helena Vaisbich; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

9.  Fabry disease in children and the effects of enzyme replacement treatment.

Authors:  Guillem Pintos-Morell; Michael Beck
Journal:  Eur J Pediatr       Date:  2009-02-26       Impact factor: 3.183

10.  Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.

Authors:  Jin-Ho Choi; Beom Hee Lee; Sun Hee Heo; Gu-Hwan Kim; Yoo-Mi Kim; Dae-Seong Kim; Jung Min Ko; Young Bae Sohn; Yong Hee Hong; Dong-Hwan Lee; Hoon Kook; Han Hyuk Lim; Kyung Hee Kim; Woo-Shik Kim; Geu-Ru Hong; Su-Hyun Kim; Sang Hyun Park; Chan-Duck Kim; So Mi Kim; Jeong-Sook Seo; Han-Wook Yoo
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.